|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 叶酸介导表没食子儿茶素没食子酸白蛋白纳米粒的制备及其体外靶向性与活性评价显示文摘研究能主动靶向于前列腺癌细胞PC-3的表没食子儿茶素没食子酸(EGCG)白蛋白(BSA)纳米粒的制备工艺与体外靶向性和活性评价。去溶剂法制备叶酸介导EGCG白蛋白纳米粒(FA-EGCG-BSANP),采用原子力显微镜(AFM)观察纳米粒形状和粒径,HPLC测定EGCG的载药量和包封率,紫外分光光度法测定叶酸偶联量,以激光共聚焦和荧光分光光度计测定FA-EGCG-BSANP对PC-3细胞的靶向性,用MTT法测定其体外活性。所得FA-EGCG-BSANP的平均粒径为200nm左右,分布均匀;EGCG的包封率可达(81.5±1.8)%,载药量为(29.3±0.6)%,叶酸偶联量为18.363μg.mg-1BSA;PC-3细胞对FA-EGCG-BSANP的摄取量为EGCG-BSANP的23.65倍,并且呈现较强的浓度依赖性;同等浓度下FA-EGCG-BSANP对PC-3细胞的抑制率为82.8%,而EGCG溶液和EGCG-BSANP分别为58.6%和55.1%,并且抑制率与PC-3细胞对这些纳米粒的摄取能力呈正相关。FA-EGCG-BSANP能明显提高EGCG对PC-3细胞的靶向效果,并提高了对细胞的致死作用,从而提高了EGCG作为一种潜在抗癌药物的治疗效果,为进一步探索该纳米粒在体内的靶向性、活性和代谢规律提供了实验基础。 | 祖元刚 袁帅 赵修华 张俞 张晓楠 姜茹 | 2009 | 药学学报2009，44，5： | 13 |
| 2 | Dialdehyde starch nanoparticles: Preparation and application in drug carrier显示文摘Dialdehyde starch nanoparticles (DASNP) were prepared by the redox reaction of NaIO4 and starch in water-in-oil microemulsion. IR spectrum showed that DASNP had aldehyde groups, and quantitative alkali consumption showed that its dialdehyde content was about (50±5)%. The average diameter of DASNP determined by SEM was about 100 nm. TGA-DTA showed that its thermal stability was better than starch nanoparticle (StNP) and dialdehyde starch (DAS). Its low biological toxicity was detected by cell experiment. Also the best mass ratio of doxorubicin (DOX) to combined DASNP detected by UV-VIS was 15 : 1, and the product was effective for controlled release of DOX. The cell experiment showed that the drug-carrier particle (DOX-DASNP) can release DOX for a long time and strengthened the effect of the anticancer drug. This work demonstrates that the DASNP, which has good thermal stability, small particle size, low biological toxicity, and slowly anticancer drug-releasing to strengthen drug effect, is a potentially useful carrier for anticancer drug. | YU DanMi XIAO SuYao TONG ChunYi CHEN Lin LIU XuanMing | 2007 | Chinese Science Bulletin2007，52，21： | 5 |
| 3 | 淀粉纳米颗粒的制备及其作为药物载体的研究进展显示文摘介绍了淀粉纳米颗粒的制备方法:机械研磨法、纳米沉淀法、超声波法、反相微乳液法、细乳液法、碱冷冻法、酶解回生法,阐述了其作为药物载体的应用,最后对淀粉纳米颗粒的发展前景进行展望。 | 孙锦 蒋文龙 何会泉 刘芳 高凤苑 蓝平 | 2018 | 现代化工2018，38，2： | 4 |
| 4 | 饲用酶制剂载体的选择和使用显示文摘饲用酶制剂作为一种绿色饲料添加剂已经受到越来越多畜牧行业从业者的青睐。市场上各种商业饲用酶制剂产品日渐增多,由于生产过程中选用的菌种、发酵方式及后处理工艺等存在差异,致使不同生产企业的同种产品理化特性和作用效果差异很大。 | 熊晓燕 訾乃涛 | 2010 | 饲料工业2010，31，18： | 4 |
| 5 | Development and application of tumor-targeting magnetic nanoparticles FA-StNP@Fe_2O_3 for hyperthermia显示文摘Modified magnetic starch nanoparticles (FA-StNP@Fe2O3) were synthesized by conjugating folic acid (FA-PEG-NH2) onto the surface of magnetic starch nanoparticles (StNP@Fe2O3) prepared by reverse microemulsion method. The synthesized FA-StNP@Fe2O3 was investigated by transmission electron microscopy and zeta potential analysis. The average size of its well dispersed particles was 250 nm. The iron concentration of 2 mg/g was detected by phenanthroline method. Placing FA-StNP@Fe2O3 nanoparticles in the alternating magnetic field for 30 min resulted in an increase in the suspension temperature from ambient temperature (37℃) to a value between 42℃ and 43℃. Co-cultured nanoparticles and Hela cell line or normal HUEC-12 cell line, and the biological effects at the cellular level were investigated in the alternating magnetic field using MTT assay, Hochest-PI double staining and flow cytometry analysis. Experimental results showed that FA-StNP@Fe2O3 within acertain concentration range has no obvious effect on cell proliferation. When treated in the magnetic field, apoptosis rate on Hela induced by FA-StNP@Fe2O3 was 13.4%. Prussian blue staining analysis confirmed that the nanoparticles modified with folic acid had improved ability in tumor cell-targeting, and therefore, potential applications in biomedical and magnetocaloric areas. It is expected be applied in tumor targeting therapy in the near future. | ZHENG YuanQing TONG ChunYi WANG Bei XIE Ying LIAO HongDong LI Dan LIU XuanMing | 2009 | Chinese Science Bulletin2009，54，17： | 3 |
| 6 | 叶酸偶联牛血清白蛋白负载卡铂和紫杉醇肿瘤靶向纳米粒制备、表征及体外释放性能评价显示文摘紫杉醇(Paclitaxel,商品名Taxol)是一种在红豆杉科(Taxaceae L.)红豆杉属(Taxus L.)生长缓慢的常绿乔木中分离提取的天然化合物。卡铂和紫杉醇均是目前临床上使用率很高的抗肿瘤药物,并在临床上经常配伍使用治疗不同的癌症。本研究以叶酸偶联的牛血清白蛋白作为药物载体,采用去溶剂技术制备了叶酸靶向卡铂—紫杉醇的白蛋白纳米粒,并研究了靶向制剂体外释放性质。研究结果表明:卡铂—紫杉醇白蛋白纳米粒平均粒径为199.4 nm,Zeta电位为-30.90 mV。卡铂包封率为91.4%;紫杉醇包封率为56.1%,药物总载药量为21%。其冻干粉复溶12 h后各项数据未发生较大变化,说明其具有良好的稳定性。体外释放结果表明叶酸—卡铂—紫杉醇白蛋白纳米粒与卡铂和紫杉醇原粉比较具有明显的缓释效果,体外释药时间可达120 h。 | 单常 祖元刚 赵修华 桑梅 | 2013 | 植物研究2013，33，4： | 2 |
| 7 | Synthesis and biochemical properties of fluorescent/magnetic bifunctional starch particles显示文摘Magnetic starch particles(MSPs) were synthesized in water-in-oil microemulsion at room temperature.MSPs were characterized by transmission electron microscopy(TEM),Fourier transform infrared spectrometry(FTIR),zeta potential system,thermogravimetric analysis(TGA) and vibrating sample magnetometry(VSM).The average diameter of the MSPs was 220 nm,dispersed with well-proportioned size and magnetic resonance,the saturation magnetization was 3.64 A·m2/kg.MSP was coated with poly-L-lysine(PLL),and then the surface of PLL-MSP was combined with fluorescein isothiocynate(FITC).Results show that fluorescent/magnetic starch particles(FMSPs) are of stable photo-bleaching capability compared with free FITC,with low bio-toxicity and certain function of magnetic separation.It is expected that FMSPs are bifunctional nano-materials including fluorescence labelling and magnetic separation. | 王凤华 刘俊 唐冬英 薛昌刚 肖苏尧 郑元青 童春义 王玲玲 刘选明 | 2010 | Journal of Central South University2010，17，2： | 1 |
| 8 | U0126纳米药物载体的制备及其用于肺动脉高压治疗显示文摘通过纳米载体增加抗收缩化合物U0126的生物利用度,以提高其抗肺动脉高压的效果。首先制备阳离子双亲淀粉包材,通过该材料构建U0126纳米药物载体,并检测其载药性能,利用体外肺动脉血管培养模型评价其在肺动脉高压治疗方面的效果。结果表明,所制备的阳离子双亲淀粉包材毒性低,可有效负载疏水性化合物U0126,载体为平均粒径(113±6.9)nm的球形胶束,包裹率达到(93.8±2.8)%,载药量为(17.4±4.6)%,在不同溶液环境中均具有良好的稳定性,且具有缓释效果。U0126纳米药物载体可有效积累于内皮细胞受损的血管壁内,而在正常血管壁中积累较少,较之游离U0126具有更好的干预效果。证明U0126纳米药物载体能显著提高药物对肺动脉高压的逆转效果。 | 李科 徐仓宝 张亚萍 张彦 | 2020 | 化工科技2020，28，4： | 1 |
| 9 | 用于肿瘤治疗和诊断的叶酸复合物显示文摘对可用于肿瘤治疗或具有潜在临床应用价值的叶酸复合物,如叶酸-基因载体,叶酸-纳米药物,叶酸-脂质体药物和可用于肿瘤诊断的叶酸-放射性核素、叶酸-核磁共振造影剂、叶酸-量子点进行了介绍,并展望了叶酸-近红外染料复合物在恶性肿瘤早期诊断方面的应用前景。叶酸受体在许多肿瘤中过度表达,而在正常组织中很少甚至几乎不表达。把化疗药物或诊断试剂开发为叶酸受体介导的叶酸复合物制剂将有可能实现对肿瘤更精准的靶向治疗和诊断。 | 刘飞 陈新洋 陈海燕 顾月清 | 2009 | 药学进展2009，33，1： | 0 |
| 10 | 叶酸偶联羟丙基壳聚糖纳米微球的制备与表征显示文摘将叶酸偶联到水溶性的羟丙基壳聚糖分子中,用离子凝胶法,与0.4,0.8,1.0,1.5,2.0g/L的多聚磷酸钠反应,形成可控粒径在130~300nm、形状规整的叶酸偶联羟丙基壳聚糖纳米微球。以牛血清蛋白为模型药物,考察了其载药效果,结果显示随着载药量的提高最大包封率达90%,载药量为47%。 | 尚晓娴 何锋其 刘焕梅 | 2008 | 中国组织工程研究与临床康复2008，12，45： | 0 |
| 11 | 羟丙基壳聚糖纳米微粒的制备(英文)显示文摘将壳聚糖与环氧丙烷反应,通过控制反应条件制备出取代度为0.56的羟丙基壳聚糖。改性后的羟丙基壳聚糖水溶性增强,将其配制成适当质量浓度的水溶液,利用离子凝胶法,与一定质量浓度的多聚磷酸钠反应,形成了粒径在500~700nm的羟丙基壳聚糖纳米微粒,透射电镜图像显示制备出的纳米微粒形状规整。 | 谢宇 尚晓娴 蒋丰兴 胡金刚 | 2008 | 中国组织工程研究与临床康复2008，12，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员